Although this report presents only one case, clinicians should consider that adverse events, including hypertension and resultant cerebral hemorrhage, can occur if plasma VEGF levels fall below the detection limit for a prolonged time during anti-VEGF therapy for DME. Here, VEGFA is linked to hypertensive disorder.